Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp to Market On-Q-ity's CTC Platform for Research

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – On-Q-ity today said that Laboratory Corporation of America will market the firm's circulating tumor cell platform to researchers in the biopharma industry.

According to the Waltham, Mass.-based firm, the technology will enable researchers to better stratify patients for potential inclusion or exclusion in clinical trials; more quickly identify patients eligible for study enrollment; better monitor cancer response to treatment; and use CTCs as an earlier indicator of treatment effectiveness.

"On-Q-ity’s CTC platform will provide researchers with a cost-effective, easy-to-use, and extremely accurate test to find and characterize tumor cells circulating in a patient’s blood," On-Q-ity CEO Mara Aspinall said in a statement.

Terms of the alliance were not disclosed.

On-Q-ity is one of several firms developing assays based on circulating tumor cells. Among the others are Advanced Cell Diagnostics and Biocept. Johnson & Johnson company Veridex already markets a circulating tumor cell test called the CellSearch system.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.